Cape Investment Advisory’s Revance Therapeutics, Inc. RVNC Stock Holding History

Cape Investment Advisory’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-350	Closed	-$1.06K	–	1203
2024 Q4	$1.06K	Hold	350	–	–	﹤0.01%	955
2024 Q3	$1.82K	Sell	350 -97	-22%	-$482	﹤0.01%	835
2024 Q2	$1.15K	Hold	447	–	–	﹤0.01%	828
2024 Q1	$2.2K	Hold	447	–	–	﹤0.01%	755
2023 Q4	$3.93K	Hold	447	–	–	﹤0.01%	816
2023 Q3	$5.13K	Sell	447 -430	-49%	-$8.27K	﹤0.01%	668
2023 Q2	$22.2K	Hold	877	–	–	0.01%	421
2023 Q1	$28.2K	Buy	+877	New	+$27.3K	0.02%	367

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cape Investment Advisory's RVNC Position: Q1 2025 in Review

Cape Investment Advisory sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 350 shares — an estimated $1.06K sold.

Cape Investment Advisory first reported a position in RVNC in Q1 2023 and held it in 8 quarters. The position peaked at $28.2K in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Cape Investment Advisory reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Cape Investment Advisory sold 350 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $1.06K.
Cape Investment Advisory first reported a position in Revance Therapeutics, Inc. in Q1 2023 and held it in 8 quarters.
Cape Investment Advisory's Revance Therapeutics, Inc. position peaked at $28.2K in Q1 2023.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Cape Investment Advisory's 13F filing for Q1 2025, filed 16 May 2025.